Richardson, Resideo director, sells $82,749 in shares By Investing.com

Resideo Technologies director Nina Richardson sold 2,789 shares at $29.67 for proceeds of $82,749 under a Rule 10b5-1 plan, leaving her with 57,886 shares. The company’s Q4 adjusted EPS of $0.50 missed the $0.77 consensus, while revenue rose 2% year over year to $1.9 billion, slightly below estimates. Full-year 2025 revenue reached a record $7.47 billion, and Q1 2026 EPS guidance of $0.58-$0.62 came in above consensus, offset by revenue guidance that was just below expectations.

Analysis

REZI is starting to look like a classic “good company, crowded trade” setup: the operating story is improving enough to support multiple expansion, but the stock has already discounted a lot of the near-term upside. The bigger implication from the insider sale is not signal quality by itself — it is that governance optics can turn from benign to a headwind once a name rerates this hard, especially when the next leg of returns depends on execution rather than multiple relief.

The more important second-order effect is the upcoming ADI separation. Spinoffs often surface hidden value, but they also force investors to re-underwrite capital allocation, margin durability, and post-separation growth rates. If ADI is the cleaner growth asset, REZI may become the residual “execution” vehicle, which can compress its multiple even if fundamentals are okay; that argues for a narrower upside path than the recent rally suggests.

Near term, the stock likely trades on guidance credibility rather than historical results. A modest beat on the next print can still disappoint if revenue inflects slower than investors now assume after a 140%+ move, so the risk is not an outright fundamental break but a de-rating from any sign that margins or demand are plateauing. Conversely, a better-than-feared post-split setup could keep the squeeze going, but that requires the market to believe 2026 is a clean acceleration year, not just a normalization year.

OPY looks like the cleaner relative expression if you want exposure to the research/rating cycle around the name: it benefits from activity and event-driven coverage while avoiding the direct multiple risk embedded in REZI. The contrarian takeaway is that the market may be overpaying for certainty on a spin that is still several months away; when a stock has already moved this much, the burden of proof shifts from “better than feared” to “materially better than consensus.”

Key Decisions for Investors

• Reduce or avoid new outright longs in REZI into the next 4-8 weeks; use any strength to trim, because the post-rally setup now offers limited reward versus a 10-15% de-rating risk if the market questions the ADI split narrative.
• If holding REZI, consider a collar into the spin window: long stock, buy 3-6 month puts ~10% OTM and finance with calls ~15-20% OTM. This preserves upside if the separation re-rates the complex while capping downside from multiple compression.
• Pair trade: long OPY / short REZI over the next 1-3 months. The thesis is that event-driven brokerage/research activity should be less exposed to spin-related valuation reset than the operating-company multiple embedded in REZI.
• For tactical traders, wait for the first post-guidance weakness to initiate any REZI exposure; the better entry is a pullback to where the stock can trade on fundamentals rather than momentum, with a favorable 2:1 or better risk/reward to the pre-spin catalyst.
• If REZI rallies another 10%+ before the separation, sell into strength rather than chase. The market is likely pricing the best-case spin outcome early, and the last leg higher probably requires a hard catalyst, not just improved sentiment.